A Novel and Efficient CD22 CAR-T Therapy Induced a Robust Antitumor Effect in Relapsed/Refractory Leukemia Patients When Combined with CD19 CAR-T Treatment as a Sequential Therapy

Preclinical investigation of the CD22 CAR-T therapy against B cell malignancies was evaluated by co-culturing CD22 CAR-T cells with tumor cell lines or primary blasts from patients in vitro and using a xenograft mouse model in vivo.